Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
Prof. Thor Edvardsen,
Discover the details of the session
The symposium was popular and very well attended. The session was co-chaired by Dr Philip Cokkinos and myself. Hypertrophic cardiomyopathy (HCM) is a relatively common inherited cardiomyopathy that can be hard to differentiate from the enlargement of the heart that can occur with elite athletes. The aim of the session was therefore to help us to better understand these differences.
Clinical and electrocardiographic featuresThe first presenter was Dr Kristina Haugaa from Oslo University Hospital in Norway, who talked about clinical and electrocardiographic features and differences between athletes.HCM has a reported prevalence of 1:500 and is a substantial contributor to sudden cardiac death in young athletes. Diagnosis of HCM is made by echocardiography and defined as septal wall thickness > 15 mm in the absence of history of hypertension or other explanatory etiologies, according to Dr. Haugaa. Hypertrophic cardiomyopathy is caused by mutations in genes encoding sarcomeric proteins and has autosomal dominant inheritance. She stressed that genetic testing is recommended in HCM patients and the yield of genetic testing is approximately 50%. A positive test facilitates family screening and follow-up, whereas a negative test does not exclude the diagnosis of HCM.Mild HCM can be challenging to differentiate from athletes’ hearts. Dr Haugaa stressed that an even bigger challenge is to evaluate whether an athlete with left ventricular (LV) hypertrophy may have underlying HCM. To discriminate the two entities, evaluation includes family history, ECG, exercise testing, echocardiography with stress test, cardiac magnetic resonance imaging (MRI) and genetic testing. Examples of features are that septal thickness rarely exceeds 15 mm in athletes and hypertrophy is symmetric. On ECG, HCM patients and athletes both show increased QRS voltage, which is frequently accompanied by bizarre ST-T changes in HCM, but not in athletes. Ethnic differences must also be considered in the evaluation of the ECG, since black athletes have more ECG changes than Caucasians.
Different echocardiographic patterns of left ventricular hypertrophyThe second presenter was Dr Nico Van de Veire from Ghent in Belgium, who told us that echocardiography has a central role in the detection and quantification of left ventricular hypertrophy (LVH). LVH can be caused by several clinical conditions including arterial hypertension, aortic stenosis, endurance training, hypertrophic cardiomyopathy and some rare conditions. Echocardiography together with clinical information, ECG and other imaging conditions will help the clinician in the diagnostic workup. For this, a comprehensive echocardiographic examination is necessary, focusing on left ventricular and right ventricular function and structure, diastolic function and evaluation of the cardiac valves. Prof Van de Veire highlighted the echocardiographic features of these conditions in his talk.
Additional value of contrast-enhanced cardiac magnetic resonanceCardiac MRI is very helpful to distinguish athlete’s heart from CHM according to Prof Berhard Gerber from Woluwe-St. Lambert in Belgium. He stressed that most athletes present with eccentric hypertrophy, characterized by increased LV end-diastolic volume index (EDVi) and right ventricular EDVi, homogenous wall thickening <13mm and maintained LV EDV/mass and wall-thickness/EDV. He convinced us that young athletes never present with late enhancement. However, late enhancement on cardiac MRI is a typical finding in HCM and other pathologies, and predicts worse outcome in these diseases. Therefore, late gadolinium enhancement can be an important factor to help distinguish athlete’s heart from HCM. Overlap of pathologies may exist, however, and there may be questions about the effect of performance-enhancing drugs (doping) on LV remodeling in athletes.
Detraining and reversal remodellingThe last presenter was Prof. François Carré from Rennes in France. He taught us that detraining will mainly result in a decrease of LV wall thickness and has less effect on LV dilatation. The detraining effect is in favor of athlete’s heart, but even an athlete’s heart might not decrease in thickness during detraining.Detraining must be completed without any significant physical training. Detraining must have a duration of 6 weeks to 6 months before we can review the results and the patients must be studied on a regular basis. He told us that cardiac MRI is probably better than echocardiography to evaluate the results of detraining.
The session was very informative about this difficult topic and the audience was active and had many questions for the presenters.
Differential diagnosis between physiologic hypertrophy of athlete's heart and hypertrophic cardiomyopathy
EUROECHO congress news article on this session.
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903Sophia Antipolis, FR
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved